SecBot SecBot
PRESS-RELEASE ·Filed Apr 30, 2026

PHAT

Phathom Pharmaceuticals
MIXED
Impact 5/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The revenue beat and maintained guidance are positive, but the large GAAP EPS miss and management's admission that Q1 was 'a bit light to internal expectations' create near-term uncertainty. Watch for weekly prescription data and Q2 2026 revenue trajectory to validate the late March/April acceleration. The path to Q3 profitability is the key catalyst.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$11.20
T+0 close · Apr 30, 2026 · via day close
Latest settled
+6.70%
T+60 · $11.95
Vs SPY
+3.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 30 $11.20entry
  2. T+1 · 7mo ago +7.23%α +7.01% · $12.01
  3. T+5 · 6mo ago +13.13%α +11.40% · $12.67
  4. T+20 · 6mo ago −7.86%α −12.82% · $10.32
  5. T+60 · 4mo ago +6.70%α +3.59% · $11.95
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Phathom reported Q1 2026 revenue of $58.3M (+104% YoY), beating the $56.8M consensus, but GAAP EPS of -$0.37 missed the -$0.19 consensus. The company maintained FY 2026 guidance of $320-$345M revenue and expects operating profitability (ex-stock comp) starting Q3 2026. Prescription trends strengthened in late March/April, but the EPS miss and 'light to internal expectations' commentary temper the top-line beat.

Key Financial Metrics

EPS
−$0.37
est −$0.19 · -94.7%
Revenue
$58.3M
est $56.8M · +2.6% · +104.4% YoY
Rating
miss
Guidance
$320M-$345M
maintained
Gross Margin
79.4%

Key Facts

  • Q1 2026 net revenue $58.3M vs $28.5M YoY (+104%), above $56.8M consensus
  • GAAP EPS -$0.37 vs consensus -$0.19 (miss of -94.7%)
  • Non-GAAP adjusted net loss per share -$0.18 vs -$1.07 YoY
  • FY 2026 guidance maintained: revenue $320-$345M, non-GAAP opex $235-$255M
  • Operating profitability (ex-stock comp) expected Q3 2026 and full year 2026
  • 268,000 total VOQUEZNA prescriptions filled in Q1 (+115% YoY)
  • Cash and equivalents $180.9M; net cash usage ~$15M in Q1
  • Phase 2 EoE trial topline results expected late Q4 2026 or early Q1 2027

Financial Impact

Revenue beat by ~$1.5M (2.6%) but GAAP EPS missed by -$0.18 (94.7% miss vs consensus). Non-GAAP adjusted net loss improved to -$14.7M from -$77.1M YoY.

revenueepsoperating expensesprescription volume

Risk Factors

  • GAAP EPS miss of -94.7% vs consensus may spook momentum traders
  • Q1 was 'light to internal expectations' despite 104% YoY revenue growth
  • Gross-to-net discount of 55-59% remains high, pressuring net revenue per script
  • Cash runway depends on achieving operating profitability by Q3 2026 as guided

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3284660

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026